The resource of antibodies and protein profiling data created as part of the HPA program has been used for biomarker discovery programs using pathology-based immunohistochemistry. More than 140 scientific manuscripts have been published, coauthored by members of the HPA effort. This includes biomarkers for both cancer diagnostics and biomarkers with prognostic value to predict clinical outcome in cancer patients.

Key publication

• Jögi A et al., Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Mod Pathol. (2009)
  PubMed: 19734850 DOI: 10.1038/modpathol.2009.124

Other selected publications

• Jonsson L et al., Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study. J Transl Med. (2011)
  PubMed: 21777469 DOI: 10.1186/1479-5876-9-114

• Magnusson K et al., SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol. (2011)
  PubMed: 21677534 DOI: 10.1097/PAS.0b013e31821c3dae

• Gremel G et al., A systematic analysis of commonly used antibodies in cancer diagnostics. Histopathology. (2014)
  PubMed: 24330150 DOI: 10.1111/his.12255

• Dragomir A et al., The role of SATB2 as a diagnostic marker for tumors of colorectal origin: Results of a pathology-based clinical prospective study. Am J Clin Pathol. (2014)
  PubMed: 24713733 DOI: 10.1309/AJCPWW2URZ9JKQJU